...
SLNMICRO

Silence Therapeutics plc

HealthcareBiotechnology
$5.44
$0.00(+0.37%)
52W$1.97
$7.78
FinancialsValuationvs ALNY
Updated Feb 28, 12:00 AM
RSI59
RS Rating32/99
Beta0.39
Volatility80%
F-Score5/9
Mkt Cap$257M
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Silence Therapeutics plc is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is weak (RS Rating: 32), showing significant lag compared to the market leaders. Earnings growth of 23% provides fundamental context to the price action. Investors should exercise caution due to high volatility (80% annualized), which requires wider risk management.

Relative Strength
32
out of 99
Lagging
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.39
vs S&P 500
LOW VOL
52W Position
60%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$5.41
50 SMA > 100 SMA$5.98
100 SMA > 150 SMA$5.75
150 SMA > 200 SMA$5.72

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$4.82+12.93%ABOVE
50 SMA$5.41+0.54%ABOVE
100 SMA$5.98-8.98%BELOW
150 SMA$5.75-5.44%BELOW
200 SMA$5.72-4.90%BELOW

Price Performance

1D+0.4%
1W+7.9%
1M+8.6%
3M-19.3%
6M+6.7%
YTD-11.5%
1Y+20.9%
3Y-22.6%
52-Week Trading Range60% from low
$5.44
52W Low$1.97
52W High$7.78

Technical Indicators

RSI (14)NEUTRAL
58.7
305070
VCP ScoreCOOL
3/10
Base depth: 59.5%

Risk Profile

Beta
0.39
52W Vol
80%
ATR
$0.40
Max DD (1Y)
-55%

Volume Analysis

Today
5
50D Avg
239.3K
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+183%
$0.90
Q1'25-1025%
$-1.80
Q2'25-76%
$-1.74
Q3'25+23%
$-1.32
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+121.82%
5 Years:+181.67%
3 Years:+51.60%
TTM:+27.20%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-0.51%

Stock Price CAGR

10 Years:-11.99%
5 Years:-26.44%
3 Years:-22.57%
1 Year:+20.89%

Return on Equity

10Y Avg:-139.4%
5Y Avg:-249.8%
3Y Avg:-194.5%
Last Year:-84.6%

Key Metrics

Market Cap$257M
Gross Margin72.7%
Net Margin-1.0%
Piotroski F-Score5/9

More SLN Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

SLN vs ALNYALNYIONSARWRCRSP

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 32 meansSLN outperformed 32% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.39 means 61% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 3/10 with COOL status.

Frequently Asked Questions

Is SLN in an uptrend right now?

SLN has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is SLN overbought or oversold?

SLN's RSI (14) is 59. The stock is in neutral territory, neither overbought nor oversold.

Is SLN outperforming the market?

SLN has a Relative Strength (RS) Rating of 32 out of 99. SLN is currently lagging the broader market.

Where is SLN in its 52-week range?

SLN is trading at $5.44, which is 70% of its 52-week high ($7.78) and 60% above its 52-week low ($1.97).

How volatile is SLN?

SLN has a Beta of 0.39 and 52-week volatility of 80%. It's less volatile than the S&P 500 - generally more stable.